Even more striking, the first clinical data from studies with the sGC stimulator zagociguat (CY-6463, formerly IW-6463) in patients with neuropsychiatric and neurodegenerative diseases showed a significant effect on cognitive performance after 2 weeks of treatment (Chris Winrow, Cambridge). This evidence concerns the gene SGCB and neurodegenerative disease.